You have 9 free searches left this month | for more free features.

adult immunoblastic large cell lymphoma

Showing 1 - 25 of >10,000

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Adult Grade III Lymphomatoid Granulomatosis, Cutaneous B-cell Non-Hodgkin Lymphoma, MALT Trial in Duarte (biological, procedure,

Active, not recruiting
  • Adult Grade III Lymphomatoid Granulomatosis
  • +23 more
  • autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells
  • +2 more
  • Duarte, California
    City of Hope Medical Center
Jan 4, 2023

Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia, Contiguous Stage II Adult Diffuse Large Cell

Active, not recruiting
  • Adult Grade III Lymphomatoid Granulomatosis
  • +71 more
  • Chicago, Illinois
  • +5 more
Oct 8, 2021

Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma

Terminated
  • Adult Grade III Lymphomatoid Granulomatosis
  • +116 more
  • brentuximab vedotin
  • +2 more
  • Chicago, Illinois
  • +2 more
Aug 30, 2021

Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia, Contiguous Stage II Adult Burkitt Lymphoma

Completed
  • Adult Grade III Lymphomatoid Granulomatosis
  • +88 more
  • Detroit, Michigan
    Barbara Ann Karmanos Cancer Institute
Apr 14, 2021

T-Cell Non-Hodgkin Lymphoma, Acute Myeloid Leukemia, Angioimmunoblastic T-cell Lymphoma Trial in Saint Louis (WU-CART-007)

Not yet recruiting
  • T-Cell Non-Hodgkin Lymphoma
  • +14 more
  • WU-CART-007
  • Saint Louis, Missouri
    Washington University School of Medicine
Jan 17, 2023

Pediatric Cancer, Hodgkin Disease, CD30-Positive DLBCL Trial in Milwaukee (anti-CD30 Bispecific Antibody-armed

Not yet recruiting
  • Pediatric Cancer
  • +11 more
  • anti-CD30 Bispecific Antibody-armed anti-CD3-Activated Autologous T-cells (CD30 biAb-AATC)
  • Milwaukee, Wisconsin
    Children's Wisconsin
Sep 14, 2022

T-cell Lymphoma, NK-Cell Lymphoma, T-cell Prolymphocytic Leukemia Trial in United States (Optional Blood Sample, Optional Nail

Recruiting
  • T-cell Lymphoma
  • +30 more
  • Optional Blood Sample
  • Optional Nail Sample
  • Duarte, California
  • +25 more
Jul 28, 2023

Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma Trial in

Completed
  • Adult Nasal Type Extranodal NK/T-cell Lymphoma
  • +20 more
  • Scottsdale, Arizona
  • +1 more
May 6, 2022

Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma, Adult Mixed Cellularity Hodgkin

Active, not recruiting
  • Adult Lymphocyte Depletion Hodgkin Lymphoma
  • +16 more
  • 6,8-bis(benzylthio)octanoic acid
  • bendamustine hydrochloride
  • Winston-Salem, North Carolina
  • +1 more
Apr 8, 2022

Peripheral T Cell Lymphoma, PTCL, Extranodal NK/T-cell Lymphoma Trial in Worldwide (Tislelizumab)

Completed
  • Peripheral T Cell Lymphoma
  • +18 more
  • Vancouver, British Columbia, Canada
  • +29 more
Apr 29, 2022

Hematopoietic/Lymphoid Cancer, Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission

Completed
  • Hematopoietic/Lymphoid Cancer
  • +135 more
  • beclomethasone dipropionate
  • +4 more
  • Hackensack, New Jersey
  • +1 more
Feb 1, 2021

HIV Infection, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Plasmablastic Lymphoma Trial in United States (procedure, drug,

Recruiting
  • HIV Infection
  • +10 more
  • Autologous Hematopoietic Stem Cell Transplantation
  • +7 more
  • La Jolla, California
  • +3 more
Dec 7, 2022

Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma Trial in

Completed
  • Adult Nasal Type Extranodal NK/T-cell Lymphoma
  • +35 more
  • Akt inhibitor MK2206
  • laboratory biomarker analysis
  • Houston, Texas
    M D Anderson Cancer Center
Oct 14, 2020

Myelodysplastic Syndrome, Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Myeloid Leukemia Trial in

Recruiting
  • Myelodysplastic Syndrome
  • +16 more
  • Computed Tomography
  • +6 more
  • Scottsdale, Arizona
  • +2 more
Feb 3, 2022

Diffuse Large Cell Lymphoma, Non-Hodgkin Lymphoma, Burkitt Lymphoma Trial run by the National Cancer Institute (NCI)

Recruiting
  • Diffuse Large Cell Lymphoma
  • +4 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Feb 2, 2023

DLBCL Trial (Polatuzumab Vedotin)

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma
  • Polatuzumab Vedotin
  • (no location specified)
Jul 12, 2023

Adult Burkitt Lymphoma, B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Burkitt Lymphoma, DLBCL

Active, not recruiting
  • Adult Burkitt Lymphoma
  • +4 more
  • Chicago, Illinois
  • +4 more
Feb 17, 2022

Large B-cell Lymphoma Trial in Houston (Prednisone, Rituximab, Cyclophosphamide)

Not yet recruiting
  • Large B-cell Lymphoma
  • Houston, Texas
    M D Anderson Cancer Center
Sep 19, 2023

Lymphoma, Non-Hodgkin, Diffuse Large B Cell Lymphoma Trial in Tianjin (CD19-targeted Chimeric Antigen Receptor(CAR) T Cells)

Recruiting
  • Lymphoma, Non-Hodgkin
  • Diffuse Large B Cell Lymphoma
  • CD19-targeted Chimeric Antigen Receptor(CAR) T Cells
  • Tianjin, Tianjin, China
    Tianjin Cancer Hospital
Nov 19, 2023

Lymphoma, T-Cell, Cutaneous, Hodgkin Disease, Lymphoma, T-Cell, Peripheral Trial (SGN-35T)

Not yet recruiting
  • Lymphoma, T-Cell, Cutaneous
  • +5 more
  • (no location specified)
Nov 2, 2023

High-Dose Methotrexate Clearance in Diffuse Large B-Cell

Recruiting
  • Central Nervous System Lymphoma
  • Diffuse Large B-Cell Lymphoma
  • Non-Interventional Study
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Sep 8, 2023

Relmacabtagene Autoleucel in Patients With LBCL

Recruiting
  • Large B-cell Lymphoma
  • Relmacabtagene Autoleucel
  • Shanghai, Shanghai, China
    Ruijin Hospital Affiliated to Shanghai Jiao Tong University Scho
Nov 15, 2023

Diffuse Large B-cell Lymphoma Recurrent, Diffuse Large B Cell Lymphoma Refractory Trial in Hangzhou (Anlotinib HCl, Rituximab,

Recruiting
  • Diffuse Large B-cell Lymphoma Recurrent
  • Diffuse Large B Cell Lymphoma Refractory
  • Anlotinib hydrochloride, Rituximab, gemcitabine, oxaliplatin
  • Hangzhou, Zhejiang, China
    Zhejiang Cancer Hospital
Oct 12, 2023

Recurrent DLBCL, Refractory Diffuse Large B-cell Lymphoma Trial in Tianjin (RC19D2 cell injection)

Recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • Refractory Diffuse Large B-cell Lymphoma
  • RC19D2 cell injection
  • Tianjin, Tianjin, China
    Hematology Hospital of the Chinese Academy of Medical Sciences
Sep 14, 2023

Lymphoma, Large B-Cell, Diffuse, Follicular Lymphoma Grade 3B, High-grade B-cell Lymphoma Trial in China (Relmacabtagene

Not yet recruiting
  • Lymphoma, Large B-Cell, Diffuse
  • +3 more
  • Relmacabtagene Autoleucel
  • +2 more
  • Guangzhou, Guangdong, China
  • +12 more
Oct 24, 2023